Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CanSino Building $317 Million Ebola Vaccine Production Facility in Tianjin

publication date: Oct 14, 2015
Tianjin CanSino Biotechnology, a company focusing on human vaccines R&D, announced that they have started construction of an industry facility in the northeastern city of Tianjin to produce a China Ebola vaccine. The vaccine is developed jointly by the Bioengineering Institute of China's Academy of Military Medical Sciences (AMMS) and Tianjin CanSino Biotechnology, and has moved onto a phase II clinical trial in Sierra Leone last Saturday. CanSino is planning to invest about $317 million into the facility and complete construction around 2017-2018. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital